232 related articles for article (PubMed ID: 18072430)
1. [Achieving Bcl-2/IgH negativity in peripheral blood/bone marrow after therapy implies better prognosis for patients with follicular lymphoma].
Belada D; Smolej L; Stepánková P; Beránek M; Dvoráková D; Bukac J; Malý J
Vnitr Lek; 2007 Oct; 53(10):1057-63. PubMed ID: 18072430
[TBL] [Abstract][Full Text] [Related]
2. Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.
Papajík T; Jedlicková K; Kriegová E; Jarosová M; Raida L; Faber E; Hubácek J; Vondráková J; Pikalová Z; Indrák K
Neoplasma; 2001; 48(6):501-5. PubMed ID: 11949845
[TBL] [Abstract][Full Text] [Related]
3. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
[TBL] [Abstract][Full Text] [Related]
4. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
5. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma.
Mahé B; Milpied N; Mellerin MP; Moreau P; Morineau N; Vigier M; Harousseau JL
Bone Marrow Transplant; 2003 Mar; 31(6):467-73. PubMed ID: 12665842
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
[TBL] [Abstract][Full Text] [Related]
7. [Rituximab (antiCD20 monoclonal antibody) and molecular-biological negativity in the treatment of patients with follicular lymphoma--a way to a cure?--Editorial].
Trnený M
Vnitr Lek; 2007 Oct; 53(10):1029-30. PubMed ID: 18072423
[No Abstract] [Full Text] [Related]
8. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy.
Martin S; Fischer C; Free M; Kurreck B; Stockinger H; Fenk R; Arnold C; Kliszewski S; Meckenstock G; Haas R; Kronenwett R
Eur J Haematol; 2005 Apr; 74(4):282-92. PubMed ID: 15777339
[TBL] [Abstract][Full Text] [Related]
9. Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas.
Soubeyran P; Hostein I; Debled M; Eghbali H; Soubeyran I; Bonichon F; Astier-Gin T; Hoerni B
Br J Cancer; 1999 Nov; 81(5):860-9. PubMed ID: 10555759
[TBL] [Abstract][Full Text] [Related]
10. Molecular characteristics and prognostic significance of Bcl-2/IgH gene rearrangement in Serbian follicular lymphoma patients.
Radojkovic M; Ristic S; Colovic M; Cemerikic-Martinovic V; Radojkovic D; Krtolica K
Neoplasma; 2008; 55(5):421-7. PubMed ID: 18665753
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance in detection of immunoglobulin heavy chain clonal rearrangement in bone marrow of patients with B cell lymphoma].
Chen ZY; Zhou XY; Zhang TM; Hong XN; Yin JL; Hu XC; Shi DR
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):183-8. PubMed ID: 19615255
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
[TBL] [Abstract][Full Text] [Related]
14. Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy.
Pulsoni A; Starza ID; Frattarelli N; Ghia E; Carlotti E; Cavalieri E; Matturro A; Tempera S; Rambaldi A; Foà R
Br J Haematol; 2007 May; 137(3):216-20. PubMed ID: 17408460
[TBL] [Abstract][Full Text] [Related]
15. BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study.
van Oers MH; Tönnissen E; Van Glabbeke M; Giurgea L; Jansen JH; Klasa R; Marcus RE; Wolf M; Kimby E; Vranovsky A; Holte H; Hagenbeek A; van der Reijden BA
J Clin Oncol; 2010 May; 28(13):2246-52. PubMed ID: 20368567
[TBL] [Abstract][Full Text] [Related]
16. A real-time (PCR) for a real life…? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice.
Janikova A; Mareckova A; Dvorakova D; Bortlicek Z; Tichy B; Navratil M; Kral Z; Pospisilova S; Mayer J
Exp Hematol; 2012 Jul; 40(7):528-539.e4. PubMed ID: 22381682
[TBL] [Abstract][Full Text] [Related]
17. Detection of bcl-2/IgH rearrangements by quantitative-competitive PCR and capillary electrophoresis.
Telatar M; Grody WW; Emmanouilides C
Mol Diagn; 2001 Sep; 6(3):161-8. PubMed ID: 11571709
[TBL] [Abstract][Full Text] [Related]
18. The bcl-2/IgH rearrangement in a population of 204 healthy individuals: occurrence, age and gender distribution, breakpoints, and detection method validity.
Schmitt C; Balogh B; Grundt A; Buchholtz C; Leo A; Benner A; Hensel M; Ho AD; Leo E
Leuk Res; 2006 Jun; 30(6):745-50. PubMed ID: 16297448
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of eight patients with primary follicular lymphoma in the duodenum].
Tsujioka T; Wada H; Yata K; Kondo T; Suemori S; Tokunaga H; Ohmori K; Kubo Y; Nakanishi H; Mikami M; Haruma K; Sadahira Y; Sugihara T
Rinsho Ketsueki; 2007 Feb; 48(2):134-9. PubMed ID: 17370641
[TBL] [Abstract][Full Text] [Related]
20. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
